The TREOCAPA trial was a multicenter, phase III study involving 14 European countries. The study investigated the preventive use of paracetamol, in preterm infants (23–26 weeks of gestation), evaluating its impact on the closure of patent ductus arteriosus as well as on common complications associated with preterm birth.
conect4children worked in close collaboration with the sponsor INSERM, ECRIN, and GFCNI, to support the study’s execution. In Portugal, the three participating sites were also supported by STAND4Kids and CETERA.
The TREOCAPA-LT trial is currently following up the children until two years of age to assess potential long-term effects on health and neurodevelopment.
Learn more about the TREOCAPA results here: https://link.springer.com/article/10.1186/s13063-025-08751-8
